Cellectar Biosciences (CLRB) stock tumbled over 17% on Tuesday after the company announced an agreement with several institutional investors to exercise certain existing warrants for gross proceeds of ...

) has been revised to $47.94 / share. This is a decrease of 44.05% from the prior estimate of $85.68 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...

XTX Topco Ltd raised its position in Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) by 122.6% in the 1st quarter, HoldingsChannel.com reports. The fund owned 104,323 shares of the ...

James V. Caruso, President and CEO, stated that Cellectar has made "significant strides across our development pipeline, regulatory strategy, corporate development initiatives and fundraising efforts, ...

Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to Anne ...

Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-3.39, expectations were $-3.6. Operator: Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions ...